With me today are Shacey Petrovic, President and Chief Executive Officer and Wayde McMillan, Executive Vice President and Chief Financial Officer. Insulet Corporation – the company that brought us the tubeless insulin pump, the OmniPod, released some exciting news a couple weeks ago which could drastically shift the future of Type 1 diabetes management as we know it. And other pumps challenged from an access perspective. For the other drivers that you mentioned, Omnipod 5, that one comes first half of the year will be our limited market release. Those -- that's really what's driving access and availability of Omnipod to the Type 2 population. Appreciate it. Our Omnipod 5 pre-school pivotal study with two to six year olds is under way with all 80 participants on product. And virtual training is quick and effective. And for patients to be able to walk into the pharmacy, get the product, have no upfront cost and have that sort of easy onboarding experience is the right time to start to learn more about DTC, and we're encouraged and stay tuned. And most importantly, we remain focused on improving the lives of people living with diabetes. And is that going to be materially different in fourth quarter? And just a reminder, Q4 in the prior year was our all-time highest new customer starts. What do you think it actually accelerates the MDI conversion part of the business? We were very happy to report just under 65%, and I think we can think about the same for Q4. 80% of new users are coming from MDI. Q4 ends up with three quarters, including Q2, which was the lowest in it. That is a population that is just very attracted to DASH and its simplicity. If we can get to the high end of our guide or even above, then new customer starts are going to be pretty strong for us in Q4. And that's why I mentioned in my remarks that we're really starting in earnest our expansion in early 2021. So those are the things that we're evaluating before we determine to what extent we increase our investment in DTC in 2021. Despite the challenging environment, our global diabetes business remains well positioned to generate strong growth this year as well as in 2021 and beyond. However, over time, it's designed that the automated manufacturing lines will be more efficient and get us lower cost product. So we remain very bullish on our expansion strategy over the long-term. This is Brianna on the Raj. It's just a much easier technology to use on young active children. So we know we've got a really appealing product. Our results were favorable in both the U.S. and international regions with the combined impact slightly less than 30%. So the question was around mix on COGS. But that's why I wanted to just share and give perspective on all the momentum we have building inside the business because there is so much good things happening. Additionally, both the U.S. and international had significant sequential improvements resulting in approximately half of the impact in Q3 versus Q2. If we see something like Q2 again, that was pretty extreme, and I think that would be something that would probably push us out of the range. In closing, I would like to acknowledge both National Diabetes Awareness Month and Insulet's 20th anniversary since our company's founding. Thanks, guys. So it's not like it was in Q2. While it will take time to broaden our presence, over the longer term, our expanded global footprint will significantly increase our total addressable market. Thank you. We didn't give the five markets, so we'll lay those out for you as we enter into them. By Ava Runge and Adam BrownExpected in 2017. And on an absolute basis, OUS maybe down marginally 5% or 10% year-over-year, but not dramatically down. But as we have the U.K. heading back into a shelter in place, France, those are a little bit more challenged environment for us, and France in particular is a large market for us. We announced recently that we have stood up another third-party manufacturing plant in China. The move into Type 2 is still early. And how far behind is Omnipod 5 outside the U.S. compared to the U.S.? And despite the headwind, it's been on the low end of our stated new customer starts headwind. And so in speaking with our field teams there, they do anticipate it's going to be more challenging. Congrats on a really good quarter. But as I said, as we lay out our expectations for 2021, we'll be able to give insight into our DTC and what we expect that that's going to drive for us. Okay. This really is a step in the eventual label expansion, and it's an early stuff. Q3 revenue included a headwind of an approximate 4 million decrease in distributor channel inventory levels, partially offsetting estimated channel inventory built in the first half of the year, mainly due to the pandemic. Although COVID to create uncertainties and it is difficult to predict the progression of the pandemic or the probability of a resurgence, we now expect the global new customer starts for the full year of 2020 will improve to approximately 75% of our beginning of the year estimate. And so I'm trying to just -- if you could walk us through any milestones or milepost we should think about? Thanks for taking the questions here. And that's the unknown and we'll obviously know more after we get through Q4 and we're setup to give our 2021 guide. Because if you think about the capital equipment model, some of those folks or most of those folks are locked into a four year contract. And so there is a lot of momentum building in behind this pandemic. As we learn more from our growing Type 2 user base, we know there is a large market for an appropriate Type 2 AIG system. And we will let you know as we enter these markets that those launches have occurred. So it's not like it's been a significant pick-up at this point. And regardless of what happens with the vaccine and the macro environment, our teams are getting great at managing and making an impact in this environment, and that's because of some of the things that Wayde just mentioned, our virtual training tools and various capabilities that we've built. We know increased awareness is key to growing adoption, and we are delighted to be in such a strong position to invest and explore this area. Our next question comes from the line of Ryan Blicker from Cowen. Hi, everyone. So we're seeing a great recovery. So if we talk about the U.S. first, we've been performing quite well in the U.S. And new customer starts have been below our beginning of year expectations in Q2 and Q3, but we've been building momentum in the business, and Q4 is going to be pretty close to Q4 in the prior year. Yeah. Good afternoon. The additional cash further strengthens our position and allows us to continue to invest in our strategic imperatives. From a mix standpoint, we'll continue to see the mix benefit in the U.S. from the pharmacy channel. Okay, that's great. I'll start with expanding access and awareness. The ​Omnipod Horizon closed loop system ​, also developed in partnership with Dexcom, is being tested pre-release in the USA - it is not expected in Canada until late 2020. tidepool.org ​ is working on getting the ​Loop ​ app (see below) approved by the US FDA and using it … We've been expanding our DTC over the last couple of years through digital channels, but this is the first time that we've really stuck our toe into television. Insulet says it expects to file mid-year, with a hopeful approval and limited launch by end of 2020 and a full commercial launch in 2021. Thanks. Yeah. They choose it over Omnipod when they do, because it has DexCom integration. 24, 2018-- Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the leader in tubeless insulin pump technology with its Omnipod® Insulin Management System (Omnipod System), today announced that positive results from the most recent clinical trial of the Omnipod® Horizon™ Automated Glucose Control System (Omnipod Horizon …